
Opinion|Videos|April 23, 2025
Importance of Primary Care in Identification and Screening for Hypercortisolism
Experts discuss how the clinical presentation of hypercortisolism differs in the primary care vs specialist setting, highlighting earlier signs/symptoms vs overt disease, and review recent data on the prevalence of hypercortisolism, including its higher occurrence in patients with difficult-to-control diabetes, difficult-to-control hypertension, and cardiovascular disease.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How would the clinical presentation of hypercortisolism differ in the primary care vs specialist setting?
- Earlier signs/symptoms vs overt disease
- The prevalence of hypercortisolism in certain at-risk patients is higher than previously thought. Can you discuss some of the recent data on hypercortisolism prevalence?
- Prevalence of hypercortisolism in patients with difficult-to-control diabetes was 24%.
- Prevalence of hypercortisolism in patients with difficult-to-control diabetes and difficult-to-control hypertension was 40%.
- Patients with cardiovascular disease had a higher prevalence of hypercortisolism than those without (33.3% vs 20.9%).
Advertisement
Related to this article

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
RAPID: Etripamil Converts Two-Thirds of Recurrent PSVT Episodes After Ablation
3
Metformin May Lower Cardiac Dysfunction Risk During VEGF Inhibitor Therapy
4
Building Trust Into Community Kidney Screening, With David Van Wyck, MD
5

